Literature DB >> 21918364

A histopathological study of pulmonary hypertension in connective tissue disease.

Nobuhito Sasaki1, Akihisa Kamataki, Takashi Sawai.   

Abstract

Connective tissue diseases (CTD), such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and mixed connective tissue disease (MCTD), develop pulmonary hypertension (PH). Generally all PH cases associated with any CTD are classified into the same PH group. However, histological examination shows both common and specific lesions for each disease. In patients with SLE, fibrosis is generally rare and mild. The findings of PH in SLE are similar to those in primary pulmonary hypertension. Many cases of SSc are accompanied by fibrosis. MCTD is rather close to SSc. Arterial and arteriolar lesions of MCTD are characterized by fibrous intimal thickening. In this review, we describe the pathological features of PH associated with each CTD.

Entities:  

Mesh:

Year:  2011        PMID: 21918364     DOI: 10.2332/allergolint.11-RAI-0337

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


  9 in total

Review 1.  Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment.

Authors:  Elisabetta Zanatta; Pamela Polito; Giulia Famoso; Maddalena Larosa; Elena De Zorzi; Elena Scarpieri; Franco Cozzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-22

Review 2.  Pulmonary hypertension in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

3.  Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension?

Authors:  Ziwei Liu; Jieying Wang; Jinzhi Lai; Qian Wang; Jiuliang Zhao; Can Huang; Xiaoxi Yang; Junyan Qian; Hui Wang; Xiaoxiao Guo; Yongtai Liu; Zhuang Tian; Mengtao Li; Yan Zhao; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2018-07-24       Impact factor: 2.980

Review 4.  Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction.

Authors:  Atiya Dhala
Journal:  Clin Dev Immunol       Date:  2012-03-22

Review 5.  Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies.

Authors:  Konstantinos Tselios; Dafna D Gladman; Murray B Urowitz
Journal:  Open Access Rheumatol       Date:  2016-12-20

6.  Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide.

Authors:  Eri Sugawara; Masaru Kato; Ryo Hisada; Kenji Oku; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
Journal:  Intern Med       Date:  2017-02-15       Impact factor: 1.271

7.  Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat.

Authors:  Kentaro Kuzuya; Soichiro Tsuji; Masato Matsushita; Shiro Ohshima; Yukihiko Saeki
Journal:  Cureus       Date:  2019-03-26

8.  Outcomes and Risk Factors of Systolic Pulmonary Artery Pressure Progression in Patients with Systemic Rheumatic Diseases: Follow-up Results from a Korean Registry.

Authors:  Mi Ryoung Seo; Jina Yeo; Hee Jung Ryu; Hyo-Jin Choi; Kwang-Pil Ko; Han Joo Baek
Journal:  Arch Rheumatol       Date:  2020-04-27       Impact factor: 1.472

9.  Pulmonary hypertension in parenchymal lung disease.

Authors:  Iraklis Tsangaris; Georgios Tsaknis; Anastasia Anthi; Stylianos E Orfanos
Journal:  Pulm Med       Date:  2012-10-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.